Market closed
Lexicon Pharmaceuticals/$LXRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Ticker
$LXRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
103
Website
LXRX Metrics
BasicAdvanced
$184M
-
-$0.63
1.05
-
Price and volume
Market cap
$184M
Beta
1.05
52-week high
$2.45
52-week low
$0.28
Average daily volume
24M
Financial strength
Current ratio
5.441
Quick ratio
5.336
Long term debt to equity
71.873
Total debt to equity
72.678
Interest coverage (TTM)
-12.65%
Management effectiveness
Return on assets (TTM)
-43.77%
Return on equity (TTM)
-167.66%
Valuation
Price to revenue (TTM)
5.249
Price to book
1.26
Price to tangible book (TTM)
1.82
Price to free cash flow (TTM)
-0.907
Growth
Revenue change (TTM)
2,481.48%
Earnings per share change (TTM)
-21.82%
3-year revenue growth (CAGR)
370.72%
3-year earnings per share growth (CAGR)
1.29%
What the Analysts think about LXRX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Lexicon Pharmaceuticals stock.
LXRX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LXRX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
LXRX News
AllArticlesVideos
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewsWire·2 weeks ago
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
Benzinga·3 weeks ago
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals (LXRX) has a market cap of $184M as of April 19, 2025.
What is the P/E ratio for Lexicon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Lexicon Pharmaceuticals (LXRX) stock is 0 as of April 19, 2025.
Does Lexicon Pharmaceuticals stock pay dividends?
No, Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Lexicon Pharmaceuticals dividend payment date?
Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.